These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 4652588)
1. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Creaven PJ; Allen LM; Muggia FM Cancer Chemother Rep; 1972 Oct; 56(5):573-8. PubMed ID: 4652588 [No Abstract] [Full Text] [Related]
2. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Muggia FM; Creaven PJ; Hansen HH; Cohen MH; Selawry OS Cancer Chemother Rep; 1972 Aug; 56(4):515-21. PubMed ID: 5081595 [No Abstract] [Full Text] [Related]
3. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Burke TG; Mi Z Anal Biochem; 1993 Jul; 212(1):285-7. PubMed ID: 8368506 [No Abstract] [Full Text] [Related]
4. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Homsi J; Simon GR; Garrett CR; Springett G; De Conti R; Chiappori AA; Munster PN; Burton MK; Stromatt S; Allievi C; Angiuli P; Eisenfeld A; Sullivan DM; Daud AI Clin Cancer Res; 2007 Oct; 13(19):5855-61. PubMed ID: 17908979 [TBL] [Abstract][Full Text] [Related]
5. The comparison of biophysical properties of DB-67 and its ester DB-67-4ABTFA determined by fluorescence spectroscopy methods. Kruszewski S; Ziomkowska B; Cyrankiewicz M; Wybranowski T Biosystems; 2008 Dec; 94(3):270-5. PubMed ID: 18718502 [TBL] [Abstract][Full Text] [Related]
6. Renal clearance of camptothecin (NSC-100880): effect of urine volume. Creaven PJ; Allen LM Cancer Chemother Rep; 1973 Apr; 57(2):175-84. PubMed ID: 4742497 [No Abstract] [Full Text] [Related]
7. Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans. Tsakalozou E; Adane ED; Liang Y; Arnold SM; Leggas M Cancer Chemother Pharmacol; 2014 Jul; 74(1):45-54. PubMed ID: 24807458 [TBL] [Abstract][Full Text] [Related]
8. Binding interactions of water-soluble camptothecin derivatives with bovine serum albumin. Li Q; Zhu Q; Deng X; He W; Zhao T; Zhang B Spectrochim Acta A Mol Biomol Spectrosc; 2012 Feb; 86():124-30. PubMed ID: 22051412 [TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva. de Jonge MJ; Verweij J; Loos WJ; Dallaire BK; Sparreboom A Clin Pharmacol Ther; 1999 May; 65(5):491-9. PubMed ID: 10340914 [TBL] [Abstract][Full Text] [Related]
10. Toxicity of camptothecin (NSC-100880). Schaeppi U; Fleischman RW; Cooney DA Cancer Chemother Rep 3; 1974 Sep; 5(1):25-36. PubMed ID: 4213507 [No Abstract] [Full Text] [Related]
11. A new approach to determine camptothecin and its analogues affinity to human serum albumin. Marszałł MP; Buciński A; Kruszewski S; Ziomkowska B J Pharm Sci; 2011 Mar; 100(3):1142-6. PubMed ID: 20740669 [TBL] [Abstract][Full Text] [Related]
12. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599 [TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. Trocóniz IF; Cendrós JM; Soto E; Pruñonosa J; Perez-Mayoral A; Peraire C; Principe P; Delavault P; Cvitkovic F; Lesimple T; Obach R Cancer Chemother Pharmacol; 2012 Aug; 70(2):239-50. PubMed ID: 22699813 [TBL] [Abstract][Full Text] [Related]
14. Scaling of camptothecin plasma protein binding in 24 species. Boxenbaum H; Fertig JB Biopharm Drug Dispos; 1984; 5(4):405-8. PubMed ID: 6525446 [No Abstract] [Full Text] [Related]
15. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632 [TBL] [Abstract][Full Text] [Related]
16. [The study of dynamic acccumulation of camptothecin in Camptotheca acuminata fruit by TLCS]. Jiang ML; Huang RS; Wu Y; Zhou FL; Su Q; Wei AY Zhong Yao Cai; 2008 May; 31(5):684-6. PubMed ID: 18826145 [TBL] [Abstract][Full Text] [Related]
17. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors. Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594 [TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410 [TBL] [Abstract][Full Text] [Related]
19. [Determination of unconjugated serum bilirubin unbound to albumin after thin layer Sephadex gel chromatography]. Trivin F; Levillain P; Lemonnier A Ann Biol Clin (Paris); 1973; 31(4):329-34. PubMed ID: 4723411 [No Abstract] [Full Text] [Related]
20. [Experimental analysis of embichin interaction with human serum albumin]. Luik AI; Novikova NV Farmakol Toksikol; 1980; 43(5):593-7. PubMed ID: 7449990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]